{"transactions":[{"id":728745,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:32:02.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001197020-26-000002","document":"wk-form4_1782246720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000119702026000002/wk-form4_1782246720.xml","form_type":"4"}},{"id":793885,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T16:35:41.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":10.0466,"value":221025.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1078391,"source":{"system":"sec-edgar","filing":"0001628280-26-029640","document":"wk-form4_1777912538.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026029640/wk-form4_1777912538.xml","form_type":"4"}},{"id":819638,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T14:46:41.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":9.0735,"value":199617.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.87 to $9.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1100391,"source":{"system":"sec-edgar","filing":"0001628280-26-022971","document":"wk-form4_1775141198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026022971/wk-form4_1775141198.xml","form_type":"4"}},{"id":867395,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T17:10:03.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":200,"price":9.98,"value":1996.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.97 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1122391,"source":{"system":"sec-edgar","filing":"0001628280-26-013630","document":"wk-form4_1772557800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026013630/wk-form4_1772557800.xml","form_type":"4"}},{"id":867394,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T17:10:03.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":21800,"price":9.5039,"value":207185.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.97 to $9.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1122591,"source":{"system":"sec-edgar","filing":"0001628280-26-013630","document":"wk-form4_1772557800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026013630/wk-form4_1772557800.xml","form_type":"4"}},{"id":879714,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-02-26T21:56:28.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":false,"shares":42377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares vested and became exercisable in 36 equal monthly installments from October 5, 2017."}],"balance_after":0,"derivative":{"exercise_price":1.485,"expiration_date":"2027-10-05","underlying":"Common  Stock","underlying_shares":42377},"source":{"system":"sec-edgar","filing":"0001628280-26-012397","document":"wk-form4_1772142986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012397/wk-form4_1772142986.xml","form_type":"4"}},{"id":879713,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T21:56:28.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":200,"price":10.26,"value":2052.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."}],"balance_after":1144391,"source":{"system":"sec-edgar","filing":"0001628280-26-012397","document":"wk-form4_1772142986.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012397/wk-form4_1772142986.xml","form_type":"4"}},{"id":879712,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T21:56:28.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":42177,"price":9.7521,"value":411314.3217,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.23 to $10.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1144591,"source":{"system":"sec-edgar","filing":"0001628280-26-012397","document":"wk-form4_1772142986.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012397/wk-form4_1772142986.xml","form_type":"4"}},{"id":879711,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T21:56:28.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":true,"shares":42377,"price":1.485,"value":62929.845,"ownership":{"direct":true},"balance_after":1186768,"source":{"system":"sec-edgar","filing":"0001628280-26-012397","document":"wk-form4_1772142986.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012397/wk-form4_1772142986.xml","form_type":"4"}},{"id":921931,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-03T17:28:45.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":7.7123,"value":169670.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.32 to $7.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1144391,"source":{"system":"sec-edgar","filing":"0001628280-26-004866","document":"wk-form4_1770139722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026004866/wk-form4_1770139722.xml","form_type":"4"}},{"id":951604,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-05T18:57:28.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":5.9265,"value":130383.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.84 to $6.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1166391,"source":{"system":"sec-edgar","filing":"0001628280-26-000320","document":"wk-form4_1767639445.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026000320/wk-form4_1767639445.xml","form_type":"4"}},{"id":983617,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-03T00:48:02.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":6.0032,"value":132070.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.87 to $6.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1188391,"source":{"system":"sec-edgar","filing":"0001628280-25-054884","document":"wk-form4_1764722880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025054884/wk-form4_1764722880.xml","form_type":"4"}},{"id":1008248,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T16:58:05.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":5.6385,"value":124047.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.51 to $5.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1210391,"source":{"system":"sec-edgar","filing":"0001628280-25-048624","document":"wk-form4_1762275483.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025048624/wk-form4_1762275483.xml","form_type":"4"}},{"id":1027364,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-02T15:53:03.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":5.8362,"value":128396.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $5.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1232391,"source":{"system":"sec-edgar","filing":"0001628280-25-043567","document":"wk-form4_1759420380.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025043567/wk-form4_1759420380.xml","form_type":"4"}},{"id":1049723,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T17:50:18.000Z","date":"2025-09-02","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":4.9914,"value":109810.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.88 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1254391,"source":{"system":"sec-edgar","filing":"0001197020-25-000005","document":"wk-form4_1756921815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000119702025000005/wk-form4_1756921815.xml","form_type":"4"}},{"id":1076333,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-04T16:27:52.000Z","date":"2025-08-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":4.9863,"value":109698.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.89 to $5.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1276391,"source":{"system":"sec-edgar","filing":"0001628280-25-037344","document":"wk-form4_1754324866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025037344/wk-form4_1754324866.xml","form_type":"4"}},{"id":1095232,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T21:03:50.000Z","date":"2025-07-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":5.1003,"value":112206.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.90 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1298391,"source":{"system":"sec-edgar","filing":"0001628280-25-034055","document":"wk-form4_1751490221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025034055/wk-form4_1751490221.xml","form_type":"4"}},{"id":1103567,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2025-06-24T01:04:04.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":144400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments."}],"balance_after":144400,"derivative":{"exercise_price":1.29,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":144400},"source":{"system":"sec-edgar","filing":"0001737287-25-000077","document":"wk-form4_1750727037.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000173728725000077/wk-form4_1750727037.xml","form_type":"4"}},{"id":1127710,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2025-06-02T23:28:45.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares subject to the stock option will vest and become exercisable in full on May 30, 2026."}],"balance_after":16000,"derivative":{"exercise_price":4.94,"exercise_date":"2026-05-30","expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-25-028900","document":"wk-form4_1748906919.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028900/wk-form4_1748906919.xml","form_type":"4"}},{"id":1127709,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T23:28:45.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on  May 30, 2026."}],"balance_after":1320391,"source":{"system":"sec-edgar","filing":"0001628280-25-028900","document":"wk-form4_1748906919.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028900/wk-form4_1748906919.xml","form_type":"4"}},{"id":1306717,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-09T01:03:47.000Z","date":"2025-01-08","kind":"sale","planned":true,"acquired":false,"shares":10960,"price":12.52,"value":137219.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 29, 2024."}],"balance_after":1312391,"source":{"system":"sec-edgar","filing":"0001628280-25-000994","document":"wk-form4_1736384620.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025000994/wk-form4_1736384620.xml","form_type":"4"}},{"id":1314897,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T21:13:51.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":3080,"price":20.91,"value":64402.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.75 to $21.06 per share. Upon request by the Commission staff, the Issuer, or a security holder of  the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,967 unvested RSUs."}],"balance_after":107976,"source":{"system":"sec-edgar","filing":"0001714899-25-000001","document":"wk-form4_1735938823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000001/wk-form4_1735938823.xml","form_type":"4"}},{"id":1369019,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-12T21:43:29.000Z","date":"2024-11-07","kind":"sale","planned":true,"acquired":false,"shares":1020,"price":30,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,967 unvested RSUs."}],"balance_after":111056,"source":{"system":"sec-edgar","filing":"0001714899-24-000217","document":"wk-form4_1731447801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000217/wk-form4_1731447801.xml","form_type":"4"}},{"id":1375529,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T21:21:27.000Z","date":"2024-11-01","kind":"sale","planned":true,"acquired":false,"shares":3080,"price":27.07,"value":83375.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $26.60 to $27.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,967 unvested RSUs."}],"balance_after":112076,"source":{"system":"sec-edgar","filing":"0001714899-24-000208","document":"wk-form4_1730841680.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000208/wk-form4_1730841680.xml","form_type":"4"}},{"id":1406659,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-16T20:17:52.000Z","date":"2024-09-13","kind":"sale","planned":true,"acquired":false,"shares":1020,"price":30,"value":30600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,967 unvested RSUs."}],"balance_after":115156,"source":{"system":"sec-edgar","filing":"0001714899-24-000199","document":"wk-form4_1726517865.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000199/wk-form4_1726517865.xml","form_type":"4"}},{"id":1415748,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-04T22:26:22.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":100,"price":25.37,"value":2537.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,967 unvested RSUs."}],"balance_after":116176,"source":{"system":"sec-edgar","filing":"0001714899-24-000198","document":"wk-form4_1725483889.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000198/wk-form4_1725483889.xml","form_type":"4"}},{"id":1415747,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-04T22:26:22.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":2980,"price":24.99,"value":74470.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.37 to $25.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,967 unvested RSUs."}],"balance_after":116276,"source":{"system":"sec-edgar","filing":"0001714899-24-000198","document":"wk-form4_1725483889.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000198/wk-form4_1725483889.xml","form_type":"4"}},{"id":1460096,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T01:13:04.000Z","date":"2024-07-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":22.86,"value":2286.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,967 unvested RSUs."}],"balance_after":119256,"source":{"system":"sec-edgar","filing":"0001714899-24-000155","document":"wk-form4_1720055578.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000155/wk-form4_1720055578.xml","form_type":"4"}},{"id":1460095,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-04T01:13:04.000Z","date":"2024-07-01","kind":"sale","planned":true,"acquired":false,"shares":2980,"price":22.12,"value":65917.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $21.86 to $22.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,967 unvested RSUs."}],"balance_after":119356,"source":{"system":"sec-edgar","filing":"0001714899-24-000155","document":"wk-form4_1720055578.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000155/wk-form4_1720055578.xml","form_type":"4"}},{"id":1486395,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-07T21:33:48.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":95541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":95541,"derivative":{"exercise_price":2.44,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":95541},"source":{"system":"sec-edgar","filing":"0001593968-24-000839","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000159396824000839/primary_01.xml","form_type":"4"}},{"id":1486394,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-07T21:33:48.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":61475,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":162575,"source":{"system":"sec-edgar","filing":"0001593968-24-000839","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000159396824000839/primary_01.xml","form_type":"4"}},{"id":1492399,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-04T22:30:50.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":17901,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":17901,"derivative":{"exercise_price":18.56,"expiration_date":"2034-05-31","underlying":"Common Stock","underlying_shares":17901},"source":{"system":"sec-edgar","filing":"0001714899-24-000138","document":"wk-form4_1717540239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000138/wk-form4_1717540239.xml","form_type":"4"}},{"id":1492398,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:30:50.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":5967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,967 unvested RSUs."}],"balance_after":122336,"source":{"system":"sec-edgar","filing":"0001714899-24-000138","document":"wk-form4_1717540239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000138/wk-form4_1717540239.xml","form_type":"4"}},{"id":1495201,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-03T16:16:59.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"derivative":{"exercise_price":10.39,"exercise_date":"2025-05-30","expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-24-026217","document":"wk-form4_1717431411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026217/wk-form4_1717431411.xml","form_type":"4"}},{"id":1495200,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-03T16:16:59.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1323351,"source":{"system":"sec-edgar","filing":"0001628280-24-026217","document":"wk-form4_1717431411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024026217/wk-form4_1717431411.xml","form_type":"4"}},{"id":1511494,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-17T20:28:33.000Z","date":"2024-05-15","kind":"sale","planned":true,"acquired":false,"shares":1674,"price":20.39,"value":34132.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted September 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,216 unvested RSUs."}],"balance_after":116369,"source":{"system":"sec-edgar","filing":"0001714899-24-000122","document":"wk-form4_1715977693.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000122/wk-form4_1715977693.xml","form_type":"4"}},{"id":1540018,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-17T21:14:39.000Z","date":"2024-04-15","kind":"sale","planned":true,"acquired":false,"shares":1666,"price":18.29,"value":30471.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted September 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,216 unvested RSUs."}],"balance_after":118043,"source":{"system":"sec-edgar","filing":"0001714899-24-000104","document":"wk-form4_1713388471.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000104/wk-form4_1713388471.xml","form_type":"4"}},{"id":1568887,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-19T20:27:41.000Z","date":"2024-03-15","kind":"sale","planned":true,"acquired":false,"shares":1666,"price":20.1,"value":33486.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.72 to $20.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,216 unvested RSUs."}],"balance_after":119709,"source":{"system":"sec-edgar","filing":"0001714899-24-000092","document":"wk-form4_1710880039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000092/wk-form4_1710880039.xml","form_type":"4"}},{"id":1633844,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-20T22:38:38.000Z","date":"2024-02-15","kind":"sale","planned":true,"acquired":false,"shares":1666,"price":18.37,"value":30604.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted September 29, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $18.24 to $18.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,216 RSUs."}],"balance_after":121375,"source":{"system":"sec-edgar","filing":"0001714899-24-000066","document":"wk-form4_1708468690.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000066/wk-form4_1708468690.xml","form_type":"4"}},{"id":1676443,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-18T23:26:08.000Z","date":"2024-01-16","kind":"sale","planned":true,"acquired":false,"shares":1666,"price":18.42,"value":30687.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $18.13 to $18.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,216 RSUs."}],"balance_after":123041,"source":{"system":"sec-edgar","filing":"0001714899-24-000041","document":"wk-form4_1705620357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000041/wk-form4_1705620357.xml","form_type":"4"}},{"id":1707333,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T00:30:37.000Z","date":"2023-12-15","kind":"sale","planned":true,"acquired":false,"shares":1666,"price":23.39,"value":38967.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,216 RSUs."}],"balance_after":124707,"source":{"system":"sec-edgar","filing":"0001714899-23-000150","document":"wk-form4_1702945827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000150/wk-form4_1702945827.xml","form_type":"4"}},{"id":1739114,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-16T23:14:00.000Z","date":"2023-11-15","kind":"sale","planned":true,"acquired":false,"shares":1666,"price":19.13,"value":31870.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,216 RSUs."}],"balance_after":126373,"source":{"system":"sec-edgar","filing":"0001714899-23-000147","document":"wk-form4_1700176428.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000147/wk-form4_1700176428.xml","form_type":"4"}},{"id":1758160,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-18T20:44:42.000Z","date":"2023-10-16","kind":"sale","planned":true,"acquired":false,"shares":1666,"price":20.66,"value":34419.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,216 RSUs."}],"balance_after":128039,"source":{"system":"sec-edgar","filing":"0001714899-23-000139","document":"wk-form4_1697661869.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000139/wk-form4_1697661869.xml","form_type":"4"}},{"id":1777389,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-19T20:45:26.000Z","date":"2023-09-15","kind":"sale","planned":true,"acquired":false,"shares":40,"price":24.35,"value":974.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.32 to $24.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 4,216 RSUs."}],"balance_after":129705,"source":{"system":"sec-edgar","filing":"0001714899-23-000138","document":"wk-form4_1695156311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000138/wk-form4_1695156311.xml","form_type":"4"}},{"id":1777388,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-19T20:45:26.000Z","date":"2023-09-15","kind":"sale","planned":true,"acquired":false,"shares":1626,"price":23.6,"value":38373.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.28 to $24.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of  the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":129745,"source":{"system":"sec-edgar","filing":"0001714899-23-000138","document":"wk-form4_1695156311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000138/wk-form4_1695156311.xml","form_type":"4"}},{"id":1803637,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T22:42:35.000Z","date":"2023-08-15","kind":"sale","planned":true,"acquired":false,"shares":1666,"price":24.3,"value":40483.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $24.07 to $24.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of\nthe Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,216 RSUs."}],"balance_after":131371,"source":{"system":"sec-edgar","filing":"0001714899-23-000126","document":"wk-form4_1692312142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000126/wk-form4_1692312142.xml","form_type":"4"}},{"id":1826901,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-19T21:09:14.000Z","date":"2023-07-17","kind":"sale","planned":true,"acquired":false,"shares":1666,"price":29.6,"value":49313.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.35 to $29.94 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,216 RSUs."}],"balance_after":133037,"source":{"system":"sec-edgar","filing":"0001714899-23-000108","document":"wk-form4_1689800946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000108/wk-form4_1689800946.xml","form_type":"4"}},{"id":1839746,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-03T20:15:34.000Z","date":"2023-06-30","kind":"sale","planned":true,"acquired":false,"shares":18000,"price":24.662,"value":443916.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.36 to $25.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1315351,"source":{"system":"sec-edgar","filing":"0001209191-23-040563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123040563/doc4.xml","form_type":"4"}},{"id":1841138,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-30T21:21:40.000Z","date":"2023-06-28","kind":"sale","planned":true,"acquired":false,"shares":1114,"price":29.98,"value":33397.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.85 to $30.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 4,216 RSUs."}],"balance_after":134703,"source":{"system":"sec-edgar","filing":"0001714899-23-000107","document":"wk-form4_1688160091.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000107/wk-form4_1688160091.xml","form_type":"4"}},{"id":1841137,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-30T21:21:40.000Z","date":"2023-06-28","kind":"sale","planned":true,"acquired":false,"shares":552,"price":29.55,"value":16311.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.85 to $29.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":135817,"source":{"system":"sec-edgar","filing":"0001714899-23-000107","document":"wk-form4_1688160091.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000107/wk-form4_1688160091.xml","form_type":"4"}},{"id":1854069,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T21:02:12.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":23224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":23224,"derivative":{"exercise_price":5.7,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":23224},"source":{"system":"sec-edgar","filing":"0001593968-23-001011","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000159396823001011/primary_01.xml","form_type":"4"}},{"id":1854068,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-15T21:02:12.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":59649,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":101100,"source":{"system":"sec-edgar","filing":"0001593968-23-001011","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000159396823001011/primary_01.xml","form_type":"4"}},{"id":1867175,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T21:59:59.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":12649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":12649,"derivative":{"exercise_price":30.92,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":12649},"source":{"system":"sec-edgar","filing":"0001714899-23-000092","document":"wk-form4_1686002389.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000092/wk-form4_1686002389.xml","form_type":"4"}},{"id":1867174,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T21:59:59.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,216 unvested RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The total reported in Column 5 has been adjusted to correct an overstatement of total holdings by 9,996 shares first reflected in a Form 4 filed on 06/02/2022."}],"balance_after":136369,"source":{"system":"sec-edgar","filing":"0001714899-23-000092","document":"wk-form4_1686002389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000092/wk-form4_1686002389.xml","form_type":"4"}},{"id":1879792,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-24T18:37:08.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":12054,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12054,"derivative":{"exercise_price":25.74,"exercise_date":"2024-05-22","expiration_date":"2033-05-21","underlying":"Common Stock","underlying_shares":12054},"source":{"system":"sec-edgar","filing":"0001209191-23-031843","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031843/doc4.xml","form_type":"4"}},{"id":1879791,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T18:37:08.000Z","date":"2023-05-22","kind":"grant","planned":false,"acquired":true,"shares":6027,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1333351,"source":{"system":"sec-edgar","filing":"0001209191-23-031843","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123031843/doc4.xml","form_type":"4"}},{"id":1961125,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-09T19:36:09.000Z","date":"2023-03-08","kind":"sale","acquired":false,"shares":17935,"price":22.585,"value":405061.975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.11 to $22.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1327324,"source":{"system":"sec-edgar","filing":"0001209191-23-017483","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123017483/doc4.xml","form_type":"4"}},{"id":2024809,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-09T16:27:21.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":627,"price":29,"value":18183.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."}],"balance_after":1345259,"source":{"system":"sec-edgar","filing":"0001209191-23-007976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123007976/doc4.xml","form_type":"4"}},{"id":2024808,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-09T16:27:21.000Z","date":"2023-02-08","kind":"sale","acquired":false,"shares":17288,"price":28.3526,"value":490159.7488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1345886,"source":{"system":"sec-edgar","filing":"0001209191-23-007976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123007976/doc4.xml","form_type":"4"}},{"id":2056526,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-11T16:40:19.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":17915,"price":25.8322,"value":462783.863,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.60 to $26.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1363174,"source":{"system":"sec-edgar","filing":"0001209191-23-002917","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919123002917/doc4.xml","form_type":"4"}},{"id":2091147,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-09T20:43:42.000Z","date":"2022-12-08","kind":"sale","acquired":false,"shares":17915,"price":25.8089,"value":462366.4435,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.38 to $26.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1381089,"source":{"system":"sec-edgar","filing":"0001209191-22-060463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122060463/doc4.xml","form_type":"4"}},{"id":2098384,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-12-02T16:50:12.000Z","date":"2022-12-01","kind":"disposition_to_issuer","acquired":false,"shares":16000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right (\"CVR\") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right (\"CVR\") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."}],"balance_after":0,"derivative":{"exercise_price":4.21,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-22-124139","document":"tm2231851-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922124139/tm2231851-6_4seq1.xml","form_type":"4"}},{"id":2098383,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-12-02T16:50:12.000Z","date":"2022-12-01","kind":"disposition_to_issuer","acquired":false,"shares":12100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right (\"CVR\") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right (\"CVR\") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."}],"balance_after":0,"derivative":{"exercise_price":7.38,"expiration_date":"2030-05-11","underlying":"Common Stock","underlying_shares":12100},"source":{"system":"sec-edgar","filing":"0001104659-22-124139","document":"tm2231851-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922124139/tm2231851-6_4seq1.xml","form_type":"4"}},{"id":2098382,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-12-02T16:50:12.000Z","date":"2022-12-01","kind":"disposition_to_issuer","acquired":false,"shares":26930,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right (\"CVR\") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"At the effective time of the merger (the \"Effective Time\"), pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Kearny Acquisition Corporation (\"Merger Sub\"), dated as of October 17, 2022, each outstanding option to purchase shares of common stock, par value $0.0001 per share, of the Issuer (\"Shares\") having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by [Continued on Note 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[Continuation of Note 1] (B) the excess, if any, of $12.50 per Share over the applicable exercise price per Share under such option and (y) one non-tradable contingent value right (\"CVR\") for each Share subject to such option immediately prior to the Effective Time (without regard to vesting), which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A."}],"balance_after":0,"derivative":{"exercise_price":7.38,"expiration_date":"2030-05-11","underlying":"Common Stock","underlying_shares":26930},"source":{"system":"sec-edgar","filing":"0001104659-22-124139","document":"tm2231851-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922124139/tm2231851-6_4seq1.xml","form_type":"4"}},{"id":2121192,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-09T16:09:14.000Z","date":"2022-11-08","kind":"sale","acquired":false,"shares":17915,"price":27.382,"value":490548.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.98 to $27.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1399004,"source":{"system":"sec-edgar","filing":"0001209191-22-056178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122056178/doc4.xml","form_type":"4"}},{"id":2139252,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-11T17:12:25.000Z","date":"2022-10-10","kind":"sale","acquired":false,"shares":17915,"price":20.6686,"value":370277.969,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.14 to $21.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1416919,"source":{"system":"sec-edgar","filing":"0001209191-22-053239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122053239/doc4.xml","form_type":"4"}},{"id":2162327,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-09T17:47:41.000Z","date":"2022-09-08","kind":"sale","acquired":false,"shares":17915,"price":21.8998,"value":392334.917,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.56 to $22.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1434834,"source":{"system":"sec-edgar","filing":"0001209191-22-049284","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122049284/doc4.xml","form_type":"4"}},{"id":2190905,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T22:26:19.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":17915,"price":30.2922,"value":542684.763,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.85 to $30.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1452749,"source":{"system":"sec-edgar","filing":"0001209191-22-045069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122045069/doc4.xml","form_type":"4"}},{"id":2208637,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-12T20:46:10.000Z","date":"2022-07-08","kind":"sale","acquired":false,"shares":5072,"price":29.5663,"value":149960.2736,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 to $29.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1470664,"source":{"system":"sec-edgar","filing":"0001209191-22-041936","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122041936/doc4.xml","form_type":"4"}},{"id":2208636,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-12T20:46:10.000Z","date":"2022-07-08","kind":"sale","acquired":false,"shares":12843,"price":28.8666,"value":370733.7438,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.42 to $29.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1475736,"source":{"system":"sec-edgar","filing":"0001209191-22-041936","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122041936/doc4.xml","form_type":"4"}},{"id":2221179,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T17:03:58.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2022. The shares underlying the option will fully vest on the earlier of (i) June 23, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders."}],"balance_after":16000,"derivative":{"exercise_price":4.21,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-22-074829","document":"tm2219359-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000110465922074829/tm2219359-3_4seq1.xml","form_type":"4"}},{"id":2227248,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T20:58:39.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":35535,"price":9.62,"value":341846.7,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments."}],"balance_after":35535,"derivative":{"exercise_price":9.62,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":35535},"source":{"system":"sec-edgar","filing":"0001214659-22-008171","document":"marketforms-56494.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000121465922008171/marketforms-56494.xml","form_type":"4"}},{"id":2227247,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T20:58:39.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":22089,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":41451,"source":{"system":"sec-edgar","filing":"0001214659-22-008171","document":"marketforms-56494.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000121465922008171/marketforms-56494.xml","form_type":"4"}},{"id":2237807,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T20:53:27.000Z","date":"2022-06-08","kind":"sale","acquired":false,"shares":500,"price":26.51,"value":13255.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."}],"balance_after":1488579,"source":{"system":"sec-edgar","filing":"0001209191-22-035428","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122035428/doc4.xml","form_type":"4"}},{"id":2237806,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T20:53:27.000Z","date":"2022-06-08","kind":"sale","acquired":false,"shares":17415,"price":25.8238,"value":449721.477,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.47 to $26.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1489079,"source":{"system":"sec-edgar","filing":"0001209191-22-035428","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122035428/doc4.xml","form_type":"4"}},{"id":2242444,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-07T00:08:44.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":17959,"derivative":{"exercise_price":24.27,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":17959},"source":{"system":"sec-edgar","filing":"0001714899-22-000094","document":"wf-form4_165456050784142.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000094/wf-form4_165456050784142.xml","form_type":"4"}},{"id":2242443,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T00:08:44.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":5986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":142149,"source":{"system":"sec-edgar","filing":"0001714899-22-000094","document":"wf-form4_165456050784142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000094/wf-form4_165456050784142.xml","form_type":"4"}},{"id":2256816,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-25T22:07:13.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":12810,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12810,"derivative":{"exercise_price":24.14,"exercise_date":"2023-05-23","expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":12810},"source":{"system":"sec-edgar","filing":"0001209191-22-031958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122031958/doc4.xml","form_type":"4"}},{"id":2256815,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T22:07:13.000Z","date":"2022-05-24","kind":"sale","acquired":false,"shares":3374,"price":23.82,"value":80368.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."}],"balance_after":1506494,"source":{"system":"sec-edgar","filing":"0001209191-22-031958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122031958/doc4.xml","form_type":"4"}},{"id":2256814,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T22:07:13.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":6405,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1509868,"source":{"system":"sec-edgar","filing":"0001209191-22-031958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122031958/doc4.xml","form_type":"4"}},{"id":2276231,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-10T21:44:13.000Z","date":"2022-05-09","kind":"sale","acquired":false,"shares":14541,"price":20.62,"value":299835.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."}],"balance_after":1503463,"source":{"system":"sec-edgar","filing":"0001209191-22-028120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122028120/doc4.xml","form_type":"4"}},{"id":2286527,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-02T20:05:34.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":3822,"price":21.49,"value":82134.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.37 to $21.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1518004,"source":{"system":"sec-edgar","filing":"0001209191-22-026399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122026399/doc4.xml","form_type":"4"}},{"id":2286526,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-02T20:05:34.000Z","date":"2022-04-28","kind":"sale","acquired":false,"shares":14093,"price":20.74,"value":292288.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.36 to $21.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1521826,"source":{"system":"sec-edgar","filing":"0001209191-22-026399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122026399/doc4.xml","form_type":"4"}},{"id":2430637,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T22:01:17.000Z","date":"2022-01-18","kind":"sale","acquired":false,"shares":15173,"price":37.3944,"value":567385.2312,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.87 to $37.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1535919,"source":{"system":"sec-edgar","filing":"0001209191-22-004083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919122004083/doc4.xml","form_type":"4"}},{"id":2462533,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-21T23:13:23.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":2401,"price":57.82,"value":138825.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."}],"balance_after":1551092,"source":{"system":"sec-edgar","filing":"0001209191-21-070835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121070835/doc4.xml","form_type":"4"}},{"id":2462532,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-21T23:13:23.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":1100,"price":56.1045,"value":61714.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.06 to $56.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1553493,"source":{"system":"sec-edgar","filing":"0001209191-21-070835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121070835/doc4.xml","form_type":"4"}},{"id":2462531,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-21T23:13:23.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":5200,"price":55.3833,"value":287993.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1554593,"source":{"system":"sec-edgar","filing":"0001209191-21-070835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121070835/doc4.xml","form_type":"4"}},{"id":2462530,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-21T23:13:23.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":1300,"price":54.3477,"value":70652.01,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.00 to $54.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1559793,"source":{"system":"sec-edgar","filing":"0001209191-21-070835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121070835/doc4.xml","form_type":"4"}},{"id":2462529,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-21T23:13:23.000Z","date":"2021-12-20","kind":"sale","acquired":false,"shares":5173,"price":51.8652,"value":268298.6796,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.70 to $52.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1561093,"source":{"system":"sec-edgar","filing":"0001209191-21-070835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121070835/doc4.xml","form_type":"4"}},{"id":2492146,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-30T21:54:18.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":15174,"price":36.8,"value":558403.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."}],"balance_after":1566266,"source":{"system":"sec-edgar","filing":"0001209191-21-067149","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121067149/doc4.xml","form_type":"4"}},{"id":2515187,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-12T21:31:39.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":660,"price":53.3,"value":35178.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $53.11 to $53.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,074 restricted stock units."}],"balance_after":126167,"source":{"system":"sec-edgar","filing":"0001714899-21-000108","document":"wf-form4_163675267254090.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000108/wf-form4_163675267254090.xml","form_type":"4"}},{"id":2515186,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-12T21:31:39.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":1006,"price":52.49,"value":52804.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $52.02 to $53.01 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,074 restricted stock units."}],"balance_after":126827,"source":{"system":"sec-edgar","filing":"0001714899-21-000108","document":"wf-form4_163675267254090.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000108/wf-form4_163675267254090.xml","form_type":"4"}},{"id":2526417,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T21:30:16.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":1666,"price":50.05,"value":83383.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $50.00 to $50.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,074 restricted stock units."}],"balance_after":127833,"source":{"system":"sec-edgar","filing":"0001714899-21-000096","document":"wf-form4_163597499893227.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000096/wf-form4_163597499893227.xml","form_type":"4"}},{"id":2538211,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-20T21:03:58.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":8503,"price":39.9083,"value":339340.2749,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1581440,"source":{"system":"sec-edgar","filing":"0001209191-21-061168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121061168/doc4.xml","form_type":"4"}},{"id":2538210,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-20T21:03:58.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":6671,"price":39.1206,"value":260973.5226,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.57 to $39.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1589943,"source":{"system":"sec-edgar","filing":"0001209191-21-061168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121061168/doc4.xml","form_type":"4"}},{"id":2563107,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-22T00:16:12.000Z","date":"2021-09-17","kind":"sale","acquired":false,"shares":3399,"price":53.06,"value":180350.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.92 to $53.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1596614,"source":{"system":"sec-edgar","filing":"0001209191-21-057152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121057152/doc4.xml","form_type":"4"}},{"id":2563106,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-22T00:16:12.000Z","date":"2021-09-17","kind":"sale","acquired":false,"shares":11775,"price":52.31,"value":615950.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.92 to $52.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1600013,"source":{"system":"sec-edgar","filing":"0001209191-21-057152","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000120919121057152/doc4.xml","form_type":"4"}},{"id":2565920,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T20:04:40.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":140,"price":54.76,"value":7666.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $54.63 to $54.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,074 restricted stock units."}],"balance_after":129499,"source":{"system":"sec-edgar","filing":"0001714899-21-000091","document":"wf-form4_163190905888608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000091/wf-form4_163190905888608.xml","form_type":"4"}},{"id":2565919,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T20:04:40.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":620,"price":53.92,"value":33430.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $53.57 to $54.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,074 restricted stock units."}],"balance_after":129639,"source":{"system":"sec-edgar","filing":"0001714899-21-000091","document":"wf-form4_163190905888608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000091/wf-form4_163190905888608.xml","form_type":"4"}},{"id":2565918,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T20:04:40.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":676,"price":53.03,"value":35848.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $52.56 to $53.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,074 restricted stock units."}],"balance_after":130259,"source":{"system":"sec-edgar","filing":"0001714899-21-000091","document":"wf-form4_163190905888608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000091/wf-form4_163190905888608.xml","form_type":"4"}}],"next_cursor":"2021-09-17T20:04:40.000000Z,2565918"}